Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Vacunas contra la enfermedad meningocócica

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOUK20161012001
Publicado:
21/10/2016
Caducidad:
21/10/2017
Resumen:
Un organismo británico de investigación en salud pública muy involucrado en resolver asuntos de salud pública, que trabaja con científicos de todo el mundo, ofrece vacunas contra la enfermedad meningocócica. La tecnología ofrece los medios de expresión de antígenos heterólogos a un nivel muy alto en las fracciones de vesícula de membrana externa (OMV) de Neisseria sp. Se buscan licenciatarios interesados en utilizar estos métodos para producir nuevas vacunas de amplio espectro para la meningitis y socios con las competencias necesarias para el desarrollo preclínico de las vacunas y pruebas posteriores en la clínica.

Details

Tittle:
Technology related to vaccines against meningococcal disease
Summary:
UK public health research organisation actively engaged in addressing public health challenges, working with scientists worldwide, offers technology related to vaccines against meningococcal disease on a license agreement basis. Seeking licensees interested in using these methods for producing new, broad-spectrum vaccines for meningitis and those with the necessary capabilities for pre-clinical development of vaccines, as well as their subsequent testing in the clinic.
Description:
The UK based organisation focuses on public health research and delivery and encourages discussions, advises government and supports action by national -Y- local government, the National Health Service and other organisations. They are the leading UK public health research organisation with national -Y- international expertise in providing solutions advice and products to support national and local public health systems.

They offer technologies related to vaccines against Neisseria meningitidis, including high level expression of antigens in outer membrane vesicle (OMV) and candidate vaccines. The technology offered provides the means of expressing heterologous antigens at very high level in the OMV fractions of Neisseria sp. Alternatively, the recombinant Neisseria can be used as a whole-cell vaccine. The technology also allows expression of non-Neisseria antigens and the use of the OMVs as a delivery vehicle which maintains the conformation of difficult to express membrane proteins.

In addition, a method has been developed that enables efficient sterile filtration of OMV without losses, by stopping clumping. This is achieved by manipulation of the charge on the OMV by altering the composition of the solution. Extensive exemplification has been achieved using antigens from commensal and pathogenic Neisseria meningitidis, including demonstration of protection in animal models. The process improvement offered by this technology can be applied to OMV-based vaccines for other infectious agents.

The organisation is committed to ensuring that its capabilities and discoveries are effectively developed and exploited in partnership with industry in order to benefit public health in the UK and globally. Whilst vaccines have undoubtedly reduced the impact of meningitis, there is still room for much improvement.

The organisation has considerable experience of forming partnerships with industry (both major companies and SMEs) and of commercialising its IP through licensing, forming joint ventures and creating spin out companies. In addition, it contributes to health through commissioned research programmes and through the maintenance of a capability to respond to future needs, it also provides national and international reference laboratories for many microbial and viral diseases.

They offer the technology on a license agreement basis to licensees interested in using these methods for producing new, broad-coverage vaccines for meningitis and those with the necessary capabilities for pre-clinical development of vaccines, as well as their subsequent testing in the clinic. This can include, research institutions, academia, industrial partners and government agencies in Europe and internationally.

Advantages and Innovations:
Whilst vaccines have undoubtedly reduced the impact of meningitis, there is still room for much improvement.
The polysaccharide conjugate vaccines for serogroups A, C W are widely used and highly effective. Protein-based vaccines are now available for serogroup B disease and show early evidence of some efficacy. However, the serogroup B vaccines are unlikely to protect against all strains of serogroup B N. meningitidis so further vaccine development is likely to be required.

The technology offered provides the means of expressing heterologous antigens at very high level in the outer membrane vesicle (OMV) fractions of Neisseria spp (species). Alternatively, the recombinant Neisseria can be used as a whole-cell vaccine. This can have the advantage of broadening protection afforded by meningococcal disease vaccines and allowing inclusion of hard to express membrane proteins. Vaccine antigens expressed in OMVs are maintained in their correct conformation and antibodies are generated to surface-exposed epitopes. This is in contrast to recombinant vaccine proteins expressed as inclusion bodies in E. coli which generate antibodies to epitopes irrelevant for protection. In addition, a method has been developed that enables efficient sterile filtration of OMV without losses, by stopping clumping.
Stage of Development:
Available for demonstration
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
International patents granted on Neisserial vaccine compositions and methods in Europe, US, Australia and Japan.

International patent granted on compositions containing OMVs in Europe, US and Australia.

Partner sought

Type and Role of Partner Sought:
Partner sought are research institutions, academia, industrial partners and government agencies from Europe and internationally. Licensees sought should be interested in using the technology/methods for producing new, broad-spectrum vaccines for meningitis. Licensees should have the necessary capabilities for pre-clinical development of vaccines, as well as their subsequent testing in the clinic.





Client

Type and Size of Client:
Other
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English

Keywords

Technology Keywords:
06001012 Investigaciones médicas
06001013 Tecnología médica / ingeniería biomédica
06001006 Vacunas humanas
06001018 Virus, virología / antibióticos / bacteriología